Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal lysine-aspirin for NSAID-exacerbated respiratory disease
2022-001611-50Phase 2Active
- Sponsor
- UZ Leuven
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lysine acetylsalicylate in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD), chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma, sponsored by UZ Leuven. Primary endpoints: Change from baseline in VAS for rhinosinusitis severity and Change from baseline in VAS for asthma severity. Started Oct 2022; status: active.
02
Drugs
lysine acetylsalicylate
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on 2022-001611-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001611-50.